JPWO2022006492A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022006492A5 JPWO2022006492A5 JP2022580142A JP2022580142A JPWO2022006492A5 JP WO2022006492 A5 JPWO2022006492 A5 JP WO2022006492A5 JP 2022580142 A JP2022580142 A JP 2022580142A JP 2022580142 A JP2022580142 A JP 2022580142A JP WO2022006492 A5 JPWO2022006492 A5 JP WO2022006492A5
- Authority
- JP
- Japan
- Prior art keywords
- substitution
- wild
- residue
- type human
- position corresponding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000006467 substitution reaction Methods 0.000 claims 194
- 101150084651 Neu2 gene Proteins 0.000 claims 109
- 102000005348 Neuraminidase Human genes 0.000 claims 21
- 108010006232 Neuraminidase Proteins 0.000 claims 21
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 20
- 239000004475 Arginine Substances 0.000 claims 17
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 16
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 16
- 102000004190 Enzymes Human genes 0.000 claims 15
- 108090000790 Enzymes Proteins 0.000 claims 15
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 14
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 14
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 13
- 108060003951 Immunoglobulin Proteins 0.000 claims 13
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 13
- 235000009582 asparagine Nutrition 0.000 claims 13
- 229960001230 asparagine Drugs 0.000 claims 13
- 108020001507 fusion proteins Proteins 0.000 claims 13
- 102000037865 fusion proteins Human genes 0.000 claims 13
- 102000018358 immunoglobulin Human genes 0.000 claims 13
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 12
- 235000003704 aspartic acid Nutrition 0.000 claims 12
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 12
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 12
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 11
- 102220048830 rs587783741 Human genes 0.000 claims 11
- 102220599935 Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1_P62G_mutation Human genes 0.000 claims 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 10
- 239000004472 Lysine Substances 0.000 claims 10
- 235000004279 alanine Nutrition 0.000 claims 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 8
- 239000004473 Threonine Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 239000004471 Glycine Substances 0.000 claims 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 7
- 229940127121 immunoconjugate Drugs 0.000 claims 7
- 229960000310 isoleucine Drugs 0.000 claims 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 6
- 235000018417 cysteine Nutrition 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 6
- 235000013922 glutamic acid Nutrition 0.000 claims 6
- 239000004220 glutamic acid Substances 0.000 claims 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 6
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 6
- 239000004474 valine Substances 0.000 claims 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 5
- 229930182817 methionine Natural products 0.000 claims 5
- 108091005804 Peptidases Proteins 0.000 claims 4
- 239000004365 Protease Substances 0.000 claims 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102220160232 rs137929972 Human genes 0.000 claims 3
- 102220068439 rs781650198 Human genes 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000006337 proteolytic cleavage Effects 0.000 claims 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 102220566486 GDNF family receptor alpha-1_Q69H_mutation Human genes 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102220500652 Phosphatidylinositol 4-phosphate 5-kinase type-1 beta_L54M_mutation Human genes 0.000 claims 1
- 239000004285 Potassium sulphite Substances 0.000 claims 1
- 102220508379 Prefoldin subunit 1_K45A_mutation Human genes 0.000 claims 1
- 102220580856 Serine/threonine-protein kinase STK11_K44R_mutation Human genes 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 102220469584 Voltage-dependent L-type calcium channel subunit beta-2_P62K_mutation Human genes 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 229950002026 girentuximab Drugs 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 102220001770 rs137852957 Human genes 0.000 claims 1
- 102200028844 rs679620 Human genes 0.000 claims 1
- 102220142342 rs779117189 Human genes 0.000 claims 1
- 102220086129 rs864622425 Human genes 0.000 claims 1
- 102220103616 rs878854701 Human genes 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047989P | 2020-07-03 | 2020-07-03 | |
| US63/047,989 | 2020-07-03 | ||
| US202163134411P | 2021-01-06 | 2021-01-06 | |
| US63/134,411 | 2021-01-06 | ||
| PCT/US2021/040240 WO2022006492A2 (en) | 2020-07-03 | 2021-07-02 | Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023532021A JP2023532021A (ja) | 2023-07-26 |
| JP2023532021A5 JP2023532021A5 (https=) | 2024-07-09 |
| JPWO2022006492A5 true JPWO2022006492A5 (https=) | 2024-07-09 |
Family
ID=79317685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580142A Pending JP2023532021A (ja) | 2020-07-03 | 2021-07-02 | プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230265406A1 (https=) |
| EP (1) | EP4176056A4 (https=) |
| JP (1) | JP2023532021A (https=) |
| KR (1) | KR20230034320A (https=) |
| CN (1) | CN115803047A (https=) |
| AU (1) | AU2021299565A1 (https=) |
| BR (1) | BR112022026720A2 (https=) |
| CA (1) | CA3173145A1 (https=) |
| IL (1) | IL299559A (https=) |
| MX (1) | MX2023000243A (https=) |
| WO (1) | WO2022006492A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102914621B1 (ko) | 2018-01-03 | 2026-01-21 | 팔레온 파마슈티칼스 인크. | 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법 |
| WO2022150516A1 (en) * | 2021-01-06 | 2022-07-14 | Palleon Pharmaceuticals Inc. | Sialidase-her2-antibody fusion proteins and methods of use thereof |
| JP2026509243A (ja) * | 2023-03-10 | 2026-03-17 | ジェネンテック， インコーポレイテッド | プロテアーゼとの融合およびその使用 |
| WO2025217138A1 (en) * | 2024-04-09 | 2025-10-16 | Palleon Pharmaceuticals Inc. | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same |
| WO2026037175A1 (zh) | 2024-08-16 | 2026-02-19 | 上海宝济药业股份有限公司 | 靶向靶细胞的复合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6198807B2 (ja) * | 2012-03-16 | 2017-09-20 | ジェネンテック， インコーポレイテッド | 操作され立体構造的に安定化されたタンパク質 |
| WO2016056913A1 (en) * | 2014-10-10 | 2016-04-14 | Enzypep B.V. | Peptide fragment condensation and cyclisation using a subtilisin variant with improved synthesis over hydrolysis ratio |
| WO2017210445A1 (en) * | 2016-06-03 | 2017-12-07 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| KR102914621B1 (ko) * | 2018-01-03 | 2026-01-21 | 팔레온 파마슈티칼스 인크. | 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법 |
| WO2022150516A1 (en) * | 2021-01-06 | 2022-07-14 | Palleon Pharmaceuticals Inc. | Sialidase-her2-antibody fusion proteins and methods of use thereof |
| US20240067729A1 (en) * | 2021-01-06 | 2024-02-29 | Palleon Pharmaceuticals Inc. | Anti-pd-l1 antibodies and fusion proteins thereof |
-
2021
- 2021-07-02 WO PCT/US2021/040240 patent/WO2022006492A2/en not_active Ceased
- 2021-07-02 JP JP2022580142A patent/JP2023532021A/ja active Pending
- 2021-07-02 CN CN202180047881.0A patent/CN115803047A/zh active Pending
- 2021-07-02 EP EP21833741.8A patent/EP4176056A4/en active Pending
- 2021-07-02 US US18/003,234 patent/US20230265406A1/en active Pending
- 2021-07-02 IL IL299559A patent/IL299559A/en unknown
- 2021-07-02 BR BR112022026720A patent/BR112022026720A2/pt unknown
- 2021-07-02 KR KR1020237003002A patent/KR20230034320A/ko active Pending
- 2021-07-02 CA CA3173145A patent/CA3173145A1/en active Pending
- 2021-07-02 AU AU2021299565A patent/AU2021299565A1/en active Pending
- 2021-07-02 MX MX2023000243A patent/MX2023000243A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7827324B2 (ja) | インターロイキン－２バリアントおよびその使用方法 | |
| US20210122805A1 (en) | Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS | |
| CA2222757C (en) | Modified/chimeric superantigens and their use | |
| JP5179689B2 (ja) | 抗体ベース融合タンパク質の循環系内半減期の増強 | |
| JP2021020905A5 (https=) | ||
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| US12497462B2 (en) | Anti-CD26 proteins and uses thereof | |
| EP3998077B1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| HRP20170595T1 (hr) | Mutanti fc protutijela koji su otporni na aktivnu proteazu | |
| CN114728040A (zh) | 新型白介素-2变体及其双功能融合分子 | |
| JPWO2021189139A5 (https=) | ||
| TW201402605A (zh) | 經蛋白酶調控之抗體 | |
| CN113631582A (zh) | 一种融合蛋白及其用途 | |
| US20230295258A1 (en) | Fusion protein comprising il-12 and anti-fap antibody, and use thereof | |
| CN104292331B (zh) | 人源抗人α干扰素抗体及其应用 | |
| CA3145676A1 (en) | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same | |
| JPWO2022006492A5 (https=) | ||
| WO2021154046A1 (ko) | pH-감응성 FC 변이체 | |
| JPWO2019121906A5 (ja) | Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片 | |
| JPWO2021003469A5 (https=) | ||
| KR102334315B1 (ko) | 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법 | |
| CA3218571A1 (en) | Methods of screening and expression of disulfide-bonded binding polypeptides | |
| JPH07278200A (ja) | ＰＥ４０Ａｂを含有するタンパク質抗ガン剤 | |
| JPWO2022150516A5 (https=) | ||
| JPWO2022150521A5 (https=) |